Entrectinib

Home/Tag: Entrectinib

Ignyta Announces Results for Potential New Cancer Treatment

Dr. Alexander Drilon of Memorial Sloan Kettering Cancer Center recently reported at AACR on a potential new cancer treatment, Entrectinib, a receptor tyrosine kinase (RTK) inhibitor developed to target tumors carrying NTRK1, NTRK2, NTRK3, [...]

By |2020-02-21T15:04:32-05:00July 12th, 2016|Clinical Trials, News, Research|
Go to Top